Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 USD | -1.85% | +11.58% | -36.34% |
May. 13 | Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating | MT |
May. 09 | Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Evolution of the average Target Price on Coherus BioSciences, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Coherus BioSciences, Inc.
Truist Securities | |
HC Wainwright | |
Baird | |
Maxim | |
Barclays | |
UBS | |
Citigroup | |
Mizuho Securities | |
JPMorgan Chase |
EPS Revisions
- Stock Market
- Equities
- CHRS Stock
- Consensus Coherus BioSciences, Inc.